Business
Pricesmart executive Sherry Bahrambeygui sells over $2 million in company stock By Investing.com
![](https://i1.wp.com/i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg?w=1200&resize=1200,0&ssl=1)
In a recent move that caught the attention of market watchers, Sherry Bahrambeygui, a key figure at Pricesmart Inc (NASDAQ:), executed a series of stock sales totaling over $2 million. Over the course of three days, Bahrambeygui, who serves on the company’s board of directors, divested a significant number of shares, signaling a notable transaction in Pricesmart’s market activity.
The sales, which took place between July 15 and July 17, 2024, saw a total of 23,141 shares of Pricesmart common stock change hands. On the first day, Bahrambeygui sold 9,500 shares at an average price of $84.374, with individual trades ranging from $84.000 to $84.700. The following day, an additional 11,000 shares were sold at an average price of $87.471, with prices per share spanning from $86.300 to $88.890. The final day witnessed the sale of 2,641 shares at an average of $89.805 each, with the trades occurring within the $88.645 to $90.100 price range.
The total value of the shares sold over this period amounted to approximately $2,000,909, reflecting a substantial transaction for the executive and the company. Following these transactions, Bahrambeygui’s direct holdings in the company have been adjusted to 47,575 shares of common stock.
Pricesmart, a prominent player in the retail-variety stores sector, is incorporated in Delaware and has its headquarters in San Diego, California. These sales by a director of the company may be of interest to current and potential investors, as executive stock transactions are often closely scrutinized for insights into a company’s financial health and the confidence of its top management.
Investors and the public can request additional details on the exact number of shares sold at each separate price from Bahrambeygui, as per the footnotes in the SEC filing. The transactions are part of the routine disclosures required by company insiders and provide transparency into the trading activities of Pricesmart’s executives.
In other recent news, PriceSmart Inc. reported promising financial results for the third quarter of fiscal year 2024. The company’s net merchandise sales reached a notable $1.2 billion, showing an 11.6% increase year-over-year. This was accompanied by a net income of $32.5 million, equivalent to $1.08 per diluted share. PriceSmart’s performance was positively influenced by membership growth, high renewal rates, and a significant increase in digital channel sales.
The company also confirmed plans for further expansion. A new warehouse club in Costa Rica is set to open in spring 2025, marking a continued focus on growth. In addition, PriceSmart is working on remodeling high-volume clubs and improving logistics through third-party distribution centers.
Analysts have noted that the company’s strategic shift towards non-food inventory and the enhancement of its omnichannel offerings are key factors in its recent success. Despite a decrease in net cash from operating activities, the company’s future plans, including the implementation of the RELEX inventory management system and the opening of four additional recycling centers in the Dominican Republic, demonstrate a commitment to sustained growth and efficiency.
InvestingPro Insights
Amidst the notable stock sales by Pricesmart Inc’s (NASDAQ:PSMT) board member Sherry Bahrambeygui, the company’s financial and market performance metrics offer a broader context for investors. Pricesmart, with a market capitalization of $2.75 billion, reflects a significant footprint in the retail-variety stores sector. The company’s P/E ratio, standing at 21.49, suggests a valuation that investors are willing to pay above the earnings per share, which may be interpreted in the context of the company’s growth prospects and current market sentiment.
InvestingPro data highlights that Pricesmart has experienced a revenue growth of 11.38% over the last twelve months as of Q3 2024, indicating a robust top-line performance. Additionally, the company has managed to maintain a healthy gross profit margin of 17.2% during the same period. These metrics, combined with a recent significant return over the last week of 12.89%, paint a picture of a company that is currently performing well in terms of both growth and profitability.
For those looking to delve deeper into Pricesmart’s financials and stock performance, InvestingPro offers additional insights. According to InvestingPro Tips, Pricesmart has been aggressively buying back shares and has raised its dividend for three consecutive years, demonstrating a commitment to returning value to shareholders. Moreover, the company has maintained dividend payments for 18 consecutive years, underscoring its financial stability and shareholder-friendly policies. It’s also worth noting that Pricesmart’s liquid assets exceed its short-term obligations, which is a positive sign of the company’s liquidity and financial health.
Investors interested in a comprehensive analysis of Pricesmart, including exclusive metrics and projections, can explore more InvestingPro Tips by visiting https://www.investing.com/pro/PSMT. There are 15 additional InvestingPro Tips available, providing a well-rounded view of the company’s performance and potential investment opportunities. Moreover, by using the coupon code PRONEWS24, readers can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking further valuable insights into the market dynamics surrounding Pricesmart Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Business
Denmark gets Novo Nordisk to lower Ozempic prices
![](https://i0.wp.com/fortune.com/img-assets/wp-content/uploads/2024/08/GettyImages-ozempic-e1723039257150.jpg?resize=1200,600&w=1200&resize=1200,0&ssl=1)
On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a leading Danish newspaper, urging the hometown company to live up to its altruistic standards by lowering U.S. prices for its blockbuster diabetes and weight loss drugs.
What Sanders didn’t realize was that Denmark, a country of 6 million, was enduring its own crisis over how to pay for the Novo Nordisk drugs Ozempic and Wegovy.
Most other developed countries, including Denmark, negotiate down drug costs for their citizens, paying prices that are a fraction of those in the United States. But when a drug is effective and expensive, pharmaceutical companies can play hardball on pricing. And Novo Nordisk did, at least initially, pushing the Danish health system to its limits.
The country’s socialized health system had for years covered Ozempic as a diabetes treatment, but in 2022 doctors began prescribing it for weight loss, too, and soon they “emptied all the money boxes in the entire public health system,” said University of Copenhagen professor Jens Juul Holst, a co-inventor of the drug.
Countries around the world are struggling with how and when to pay for Ozempic, Eli Lilly’s Mounjaro, and other drugs in the same chemical class, particularly when they are prescribed for weight loss. Indeed, the sky-high prices paid in the U.S. set a bar that pharmaceutical companies can use as they negotiate with other health systems.
In Denmark, with prescriptions for the drugs gobbling up 18% of regional drug budgets in 2023, officials were considering the unthinkable in a system that prides itself on free cradle-to-grave coverage: forcing patients to pay out-of-pocket for Ozempic — a drug made in the country.
In America, meanwhile, tightening insurance policies are making it harder for patients to get the drugs, which are listed at up to $1,350 a month.
“There are changes month to month in our clinic in terms of the supply, coverage, which drug is available,” said Michael Blaha, director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. He said that doctors and patients were “playing a constant game of prior authorization and appeals.”
In particular, use of the drugs for weight loss is a hot-button issue. Novo Nordisk and Lilly are battling for coverage — joined by some doctors and patient advocate groups, many funded by the drug companies. They are pressing to overturn a 2005 federal rule that prohibits Medicare from reimbursing weight loss treatments.
“There’s a strong assumption that Medicare is going to cover these drugs for obesity treatment sooner or later,” said David Kim, an assistant professor of medicine and public health sciences at the University of Chicago. If Medicare pays, he added, commercial insurers will probably follow suit.
The impact on federal and commercial insurance budgets, he said, depends on three unanswered questions: How many people will eventually get the drugs? For how long will they take them? And at what price?
The potential Medicare market alone is enormous. In 2020 about 13.7 million Medicare beneficiaries, around a quarter of the total, were diagnosed as overweight or obese, according to Juliette Cubanski and Tricia Neuman, researchers at KFF, a health information nonprofit that includes KFF Health News. Assuming a 50% discount on a $1,300 monthly list price for Wegovy, that’s a $107 billion price tag. The entire federal share of Medicare Part D spending in 2024 was projected to be $120 billion.
Novo Nordisk spent $7.6 million lobbying Congress over the past 12 months, and lobbying disclosures show that most of that was to promote bills in the House and Senate to expand use of the GLP-1 drugs.
Pressure from drugmakers has been relentless. Pfizer, which has a GLP-1 drug in development, commissioned a white paper by consultancy Manatt arguing that Medicare law already allows payment for these anti-obesity drugs, since they have benefits beyond weight loss. Novo and other pharmaceutical companies have funded research that shows health care savings on chronic disease through use of the drugs.
But the Congressional Budget Office, whose judgments about the cost of such policies weigh heavily in whether they are eventually adopted, has yet to give a final opinion. In a March presentation, the office said it was “not aware of empirical evidence that directly links the use of anti-obesity medicines to reductions in other health care spending.”
Prime Therapeutics, a pharmacy benefit manager whose clients are employers that fund drug plans, released a study this year finding that only a third of patients put on a GLP-1 drug stayed on it for a full year. That means insurance coverage of the drugs could sometimes be a waste of money, said Patrick Gleason, Prime Therapeutics’ leader of research, since research shows that patients tend to gain the weight back after cessation.
That doesn’t completely surprise Holst, the Danish scientist, who said the GLP-1 drugs’ suppression of appetite is for many people “so miserably boring that you can’t stand it any longer and you have to go back to your old life.”
One answer might be weight loss programs that employ the GLP-1s for, say, a year, followed by maintenance therapy with cheaper drugs, Kim said.
One way or another, many experts in the field say, it’s sensible to cover weight loss before the onset of the chronic illnesses associated with obesity, like Type 2 diabetes.
Indeed, because obesity is associated with so many comorbidities, drugmakers are now doing studies showing that GLP-1 drugs also show positive impact on conditions like sleep apnea and heart, liver, and kidney diseases.
Yet even advocates for the drugs’ use acknowledge uncertainty about how long it would take for such health benefits to kick in, or whether shorter-term use would prevent or ameliorate longer-term illnesses.
“Modeling the impacts is complicated,” said Alison Sexton Ward, a research scientist at the University of Southern California’s Schaeffer Center for Health Policy and Economics. “Medical costs won’t go down immediately. The prevented diseases may be years in the future.”
Starting next year, Medicare beneficiaries’ Part D out-of-pocket costs will be capped at $2,000, meaning U.S. taxpayers will foot the bill for most Medicare drug expenses. So it’s no surprise the Congressional Budget Office believes the government will launch Medicare price negotiations for semaglutide under the Inflation Reduction Act “within the next few years,” per its March presentation.
According to the terms of the act, Ozempic would be eligible for government price negotiation as early as next year, with new prices reflected in 2027. The negotiated unit price would apply to all forms of the drug — Ozempic; its higher-dose, weight loss-branded version, Wegovy; and a pill, Rybelsus.
Where the price would land is unclear. Wegovy costs patients up to $365 a month in Denmark, which typically doesn’t cover the drug — and about $140 in Germany and $92 in the U.K.
Meanwhile, generic drugmakers are gearing up to sell their versions of semaglutide. Those appear set to go on sale in China and Brazil as early as 2026. Americans are likely to have to wait until at least 2032 because of U.S. patent restrictions. The Federal Trade Commission has tried to nibble at the drugs’ exclusivity periods by challenging Novo Nordisk patent filings on applicators used to inject the drugs — which would extend their market exclusivity up to 30 months.
For now, patients who can’t afford or access the drugs often turn to compounded forms, which are not FDA-approved although their raw material comes from FDA-registered factories. Blaha has “a number of patients” who can’t access the branded drugs and show up at the clinic with compound drug vials.
Two weeks before Sanders published his letter in Denmark, Novo Nordisk cut the local price of Ozempic by 34%, to $130 a month — about 15% of its U.S. list price. The government, which had warned it would stop paying for the drug, agreed to cover Ozempic diabetes treatment, but only for patients who had first tried a cheaper medicine such as metformin.
Wegovy, the same medicine but at a higher dose, targeted to weight loss, would in nearly all cases remain the patient’s responsibility at $365 monthly, a price that, while modest by U.S. standards, has sparked intense discussions about the uneven impact of class on its affordability, said Nils Jakob Knudsen, an endocrinologist in Copenhagen.
The calculus of the drugs’ price is complex for the Danes, he added, because “the blooming economy for Novo is also driving our very healthy Danish economy.”
Novo Nordisk’s market valuation of $591 billion on Aug. 2 was considerably higher than the entire GDP of Denmark.
Business
Weekly mortgage refinance demand soars 16% as rates sink to lowest level in over a year
![](https://i3.wp.com/image.cnbcfm.com/api/v1/image/107379313-1709073042993-gettyimages-1556374314-dji_0410_ukx1l6ut.jpeg?v=1721771811&w=1920&h=1080&w=1200&resize=1200,0&ssl=1)
An aerial view shows a subdivision that has replaced the once rural landscape in Hawthorn Woods, Illinois.
Scott Olson | Getty Images
Mortgage interest rates dropped last week to the lowest level since May 2023, causing a surge in mortgage demand from both homebuyers and especially current homeowners.
Total mortgage application volume rose 6.9% last week compared with the previous week according to the Mortgage Bankers Association’s seasonally adjusted index. Volume was at the highest level since January of this year.
The average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances ($766,550 or less) decreased to 6.55% from 6.82%, with points decreasing to 0.58 from 0.62 (including the origination fee) for loans with a 20% down payment.
“Mortgage rates decreased across the board last week…following doveish communication from the Federal Reserve and a weak jobs report, which added to increased concerns of an economy slowing more rapidly than expected,” said Joel Kan, MBA’s vice president and deputy chief economist in a release.
Applications to refinance a home loan, which are most sensitive to weekly rate changes, jumped 16% for the week and were 59% higher than the same week one year ago. While the percentage increases are large, they are still coming off a very small base. The vast majority of borrowers today have loans with rates below 5%. There are less than one million borrowers who can benefit from a refinance and shave at least 75 basis points off their current rate.
Applications for a mortgage to purchase a home increased just 1% for the week but were still 11% lower than the same week one year ago.
“Despite the downward movement in rates, purchase activity only saw small gains, with an increase in conventional purchase applications offset by decreases in government purchase applications. For-sale inventory is beginning to increase gradually in some parts of the country and homebuyers might be biding their time to enter the market given the prospect of lower rates,” added Kan.
Mortgage rates fell further to start this week, following a stock market rout Monday. They rose sharply again, however, on Tuesday following some more positive economic data.
“This is how things often play out when the bond market forces a quick move to extreme rate levels. For example, several of the biggest drops in daily mortgage rates have followed quick moves to long-term highs,” wrote Matthew Graham, chief operating officer at Mortgage News Daily.
Business
Further rate cuts could fuel house price rises, says Halifax
![](https://i1.wp.com/ichef.bbci.co.uk/news/1024/branded_news/d761/live/8e7058a0-547c-11ef-aebc-6de4d31bf5cd.jpg?w=1200&resize=1200,0&ssl=1)
Lower mortgage rates and more interest rate cuts could fuel a “modest” rise in house prices for the rest of this year, Halifax has said.
The mortgage lender’s prediction came after property prices increased marginally in July following a flat few months.
Halifax said recent mortgage rate drops were “encouraging” for first-time buyers, those moving along the housing ladder or those refinancing.
But it warned affordability challenges and lack of available properties still posed problems for buyers.
“Against the backdrop of lower mortgage rates and potential further [Bank of England] base rate reductions, we anticipate house prices to continue a modest upward trend throughout the remainder of this year,” Amanda Bryden, head of mortgages at Halifax said.
Last week the Bank of England lowered interest rates to 5% – the first cut since the start of the pandemic in March 2020.
The Bank’s rate dictates the cost of borrowing set by High Street banks and money lenders for the likes of mortgages and credit cards.
The UK’s largest lender said a typical property cost £291,268 in July, up more than £2,200 compared to the previous month.
-
African History5 years ago
A Closer Look: Afro-Mexicans 🇲🇽
-
African History7 months ago
Black History Facts I had to Learn on My Own pt.6 📜
-
African History5 years ago
A Closer Look: Afro-Mexicans 🇲🇽
-
African History1 year ago
Major African Tribes taken away during the Atlantic Slave Trade🌍 #slavetrade #africanamericanhistory
-
African History1 year ago
Cameroon 🇨🇲 World Cup History (1962-2022) #football #realmadrid #shorts
-
African History1 year ago
What did Columbus Find in 1493? 🤯🔥🔥 #history #civilization #mesoamerica #africa #kemet
-
African History7 months ago
Black History Inventors: Mary Kenner 🩸
-
African History1 year ago
Origin Of ‘Cameroon’ 🇨🇲😳#africa